Envudeucitinib (ESK-001)
Provider 
Founded 2021
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Equity, Venture Capital

Envudeucitinib (ESK-001) is Alumis's oral allosteric TYK2 inhibitor in Phase 3 development for moderate to severe plaque psoriasis.
Envudeucitinib is a next-generation, highly selective oral tyrosine kinase 2 inhibitor precision-engineered for maximal 24-hour inhibition of IL-23- and IL-17-driven inflammation. The pivotal Phase 3 ONWARD1 and ONWARD2 trials met all primary and secondary endpoints in moderate to severe plaque psoriasis, and the ONWARD3 long-term extension showed durable, high rates of skin clearance through 48 weeks.
Alumis plans to submit a U.S. new drug application for plaque psoriasis in the fourth quarter of 2026. The candidate is investigational and not yet approved by any regulatory agency.
| Attribute | Envudeucitinib (ESK-001) | ARTS-011 (TYK2 allosteric inhibitor) | Fadeucravacitinib (ICP-488) | Sotyktu (deucravacitinib) | Zasocitinib (TAK-279) | |
|---|---|---|---|---|---|---|
| Provider | ||||||
| Founded | 2021 | 2020 | 2015 | 1887 | 1781 | |
| Sells To | Enterprise | Enterprise | — | Consumers, Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring, Software | — | Recurring, Software | — | |
| Ownership | Equity, Venture Capital | Private | — | Public | Venture Capital |
Provider 
Founded 2021
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Equity, Venture Capital
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Provider 
Founded 2015
Sells To —
Pricing Model —
Ownership —
Provider Bristol Myers Squibbbms.com10.6B raised · Public
Founded 1887
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 1781
Sells To Enterprise
Pricing Model —
Ownership Venture Capital